Assessment scope
Environmental Risk Assessment (ERA)
ToxWriter provides project-specific support for the Solifenacin Environmental Risk Assessment (ERA) (the Solifenacin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
- Product, active-substance identity, formulation, route and intended-market review.
- Phase I environmental exposure screening and applicable trigger evaluation.
- Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
- PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
- Data-gap analysis, study strategy, assumptions and scientific reporting.
